start-ver=1.4 cd-journal=joma no-vol=73 cd-vols= no-issue=4 article-no= start-page=307 end-page=313 dt-received= dt-revised= dt-accepted= dt-pub-year=2019 dt-pub=201908 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Impact of Disease Complexity on Cardiovascular Events after the Transition to an Adult Congenital Heart Disease Specialized Medical Unit en-subtitle= kn-subtitle= en-abstract= kn-abstract= The follow-up of patients with adult congenital heart disease (ACHD) at a specialized medical unit is necessary for the patients’ appropriate medical care. However, limited information is available about cardiovascular events among ACHD patients. Here we investigated the type and frequency of cardiovascular events in ACHD patients in relation to disease complexity. We retrospectively analyzed the cases of 535 patients (median age 35 years) referred to our ACHD center between 2014 and 2017. We divided the patients into 3 groups based on their disease complexity. To evaluate the relationship between disease complexity and cardiovascular events, we performed univariate and multivariate survival analyses. The Simple, moderate, and complex disease groups accounted for 62%, 19%, and 19% of the patients, respectively. Apart from events related to atrial septal defect (ASD) trans-catheter treatment, the frequency of cardiovascular events was dependent on the disease complexity (event-free survival rates at 3 years were 85%, 65%, and 58%, respectively). The hazard ratios were 4.0 and 5.1 in the moderate and complex groups, respectively. With the exception of scheduled transcatheter intervention, cardiovascular events were strongly related to the disease complexity of original heart disease. However, cardiovascular events were not rare even in the simple ACHD group. en-copyright= kn-copyright= en-aut-name=TakahashiSho en-aut-sei=Takahashi en-aut-mei=Sho kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=AkagiTeiji en-aut-sei=Akagi en-aut-mei=Teiji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=TohNorihisa en-aut-sei=Toh en-aut-mei=Norihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=TakayaYoichi en-aut-sei=Takaya en-aut-mei=Yoichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=NakagawaKoji en-aut-sei=Nakagawa en-aut-mei=Koji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=NishiiNobuhiro en-aut-sei=Nishii en-aut-mei=Nobuhiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=ItoHiroshi en-aut-sei=Ito en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= affil-num=1 en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=3 en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=5 en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=6 en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=7 en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= en-keyword=congenital heart defect kn-keyword=congenital heart defect en-keyword=congenital in adults kn-keyword=congenital in adults en-keyword=hospitalization kn-keyword=hospitalization en-keyword=cardiovascular event kn-keyword=cardiovascular event END start-ver=1.4 cd-journal=joma no-vol=54 cd-vols= no-issue=5 article-no= start-page=217 end-page=225 dt-received= dt-revised= dt-accepted= dt-pub-year=2000 dt-pub=200010 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Biochemical modulation of 5-fluorouracil with a streptococcal preparation, OK-432, against murine colon-26 carcinoma. en-subtitle= kn-subtitle= en-abstract= kn-abstract=

Conventional therapy for colorectal carcinoma using 5-fluorouracil (5-FU) has shown limited antitumor action. The purpose of our study was to investigate synergistic antitumor effects of the streptococcal preparation of OK-432 and 5-FU, and to elucidate the mechanisms of interaction between the 2 agents in mice. Biochemical modulation of OK-432 and 5-FU were determined in vivo against colon-26 carcinoma. The concentration of 5-FU and its metabolites, and the activity of thymidylate synthase and thymidine kinase, respectively, were measured using cytosolic extracts of the tumors. Combination treatment with OK-432 produced a significant increase in intratumor 5-FU and 5-FU in RNA (F-RNA) concentrations, increased the thymidylate synthetase inhibition rate, and decreased thymidine kinase activity, as compared with the results observed in the control mice. These additive antitumor effects are obtained by use of the 2 agents; the mechanism of action is considered to be the suppression of both the de novo and the salvage pathway for DNA synthesis, along with the suppression of RNA synthesis.

en-copyright= kn-copyright= en-aut-name=FunakiMasato en-aut-sei=Funaki en-aut-mei=Masato kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=GouchiAkira en-aut-sei=Gouchi en-aut-mei=Akira kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=IwagakiHiromi en-aut-sei=Iwagaki en-aut-mei=Hiromi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MorimotoYoshinori en-aut-sei=Morimoto en-aut-mei=Yoshinori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=ShimamuraHiroshi en-aut-sei=Shimamura en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=ArikiNorifumi en-aut-sei=Ariki en-aut-mei=Norifumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=TanakaNoriaki en-aut-sei=Tanaka en-aut-mei=Noriaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University en-keyword=OK-432 kn-keyword=OK-432 en-keyword=5-FU kn-keyword=5-FU en-keyword=biochemical modulation kn-keyword=biochemical modulation END start-ver=1.4 cd-journal=joma no-vol=33 cd-vols= no-issue=6 article-no= start-page=471 end-page=478 dt-received= dt-revised= dt-accepted= dt-pub-year=1979 dt-pub=197912 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Immuno-chemotherapy of malignant lymphoma using OK-432, a streptococcal agent en-subtitle= kn-subtitle= en-abstract= kn-abstract=

Clinical trials of immuno-chemotherapy were conducted on malignant lymphoma patients. Patients during the period from 1972 through 1977 were allocated to two groups retrospectively according to the mode of treatment, i.e., chemotherapy alone (historical control group, 35 patients) and chemotherapy with OK-432 (treated group, 15 patients). Comparisons were made of the two groups, which were homogeneous with regard to induction chemotherapy, maintenance chemotherapy, stage and histologic type of disease. The treated group had a higher remission rate, and a longer remission duration and survival than the control groups, especially in patients with Hodgkin's disease but the difference was not statistically significant owing to the limited number of cases.

en-copyright= kn-copyright= en-aut-name=KimuraIkuro en-aut-sei=Kimura en-aut-mei=Ikuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OhnoshiTaisuke en-aut-sei=Ohnoshi en-aut-mei=Taisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=NakataYasunari en-aut-sei=Nakata en-aut-mei=Yasunari kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=TakasugiKenta en-aut-sei=Takasugi en-aut-mei=Kenta kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=FujiiMasafumi en-aut-sei=Fujii en-aut-mei=Masafumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=HayashiKyoichi en-aut-sei=Hayashi en-aut-mei=Kyoichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=KataokaMikio en-aut-sei=Kataoka en-aut-mei=Mikio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=SatoMasaharu en-aut-sei=Sato en-aut-mei=Masaharu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=NishiharaRyuji en-aut-sei=Nishihara en-aut-mei=Ryuji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Okayama University affil-num=4 en-affil= kn-affil=Okayama University affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University en-keyword=malignant lymphoma kn-keyword=malignant lymphoma en-keyword=chemotherapy kn-keyword=chemotherapy en-keyword=nonspecific immunotherapy kn-keyword=nonspecific immunotherapy en-keyword=OK-432 kn-keyword=OK-432 END start-ver=1.4 cd-journal=joma no-vol=102 cd-vols= no-issue=1-2 article-no= start-page=209 end-page=216 dt-received= dt-revised= dt-accepted= dt-pub-year=1990 dt-pub=199002 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Amplification and expression of myc-related oncogenes n adenovirus-induced tumors kn-title=アデノウイルス誘発マウス腫瘍における myc 群癌遺伝子の増幅と発現 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Amplification and expression of myc-related oncogenes were studied on adenovirus-induced tumors (D and IC) and spontaneous hapatoma (P), all of which had been successively trans-planted in C3Hf/OK mice. c-myc expression waas elevated in the D, IC anf P tumors, and a 8.9-fold amplification of c-myc was observed in the IC tumor. In the D tumor N-myc expression was elevated and a 1.9-fold amplification of N-myc was also observed. Amplification of c-myc in the IC tumor was suspected to be a result of selection for c-myc amplified cells during successive transplantation. Although expression of genes, c-myc, N-myc and E1A of adenovir-us, suppress each other, the results of this experiment, especially elevated expression of N-myc and c-myc in the D tumor, implicated deregulation of myc family genes in malignancies indiced by adenovirus. en-copyright= kn-copyright= en-aut-name=OkinoTakeshi en-aut-sei=Okino en-aut-mei=Takeshi kn-aut-name=沖野毅 kn-aut-sei=沖野 kn-aut-mei=毅 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=香川医科大学病理学講座第一病理学 en-keyword=アデノウイルス kn-keyword=アデノウイルス en-keyword=癌遺伝子 kn-keyword=癌遺伝子 en-keyword=c-myc kn-keyword=c-myc en-keyword=N-myc kn-keyword=N-myc END start-ver=1.4 cd-journal=joma no-vol=104 cd-vols= no-issue=3-4 article-no= start-page=259 end-page=266 dt-received= dt-revised= dt-accepted= dt-pub-year=1992 dt-pub=1992 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Experimental and clinical studies on interferon and its inducers Part 2. β-carboxyethylgermanium sesquioxide (Ge-132) in the management of acute nonlymphocytic leukemia patients at remission phase kn-title=インターフェロン並びにインターフェロン誘発剤に関する基礎的・臨床的研究 第2編 急性非リンパ性白血病寛解期における β-Carboxyethylgermanium sesquioxide (Ge-132) の臨床効果 en-subtitle= kn-subtitle= en-abstract= kn-abstract=The clinieal of Ge-132 in the management of acute nonlymphocytic leukemia (ANLL) patients at remission phase were studied. Twenty-two ANLL patients with complete remission were randomized into Groups A and B. Patients in Group A were treated with the combianation with Ge-132 (2,250mg/day ; p. o daily) and intermittent-alternating chemotherapy 〔daunorubicin, vincristine, cytosine arabinoside and prednisolone (DVCP)/aclarubicin vincristine cytosine arabinoside and prednisolone (AVCP)〕and patients in Groyp B were treated with intermittent-alter nating chemotherapy (DVCP/AVCP) alone. Evaluable patients were 7 in Group A and 10 in Group B. Remission duration and survival time were not significantly different between Groups A and B. (median remission duration ; 5.7 month in Group A vs 8.1 month in Group B/median surival time ; 23.9month in Group A vs 18.3month in Group B) The rates of second remission in relapsed cases were not significantly different between Groups A and B.〔2 of 7,(28.6%) in Group A vs 3 of 10,(30.0%) in B〕Ge-132 did not accelerate the recovery from myelosuppression after intensification with the DVCP regimen. The incidence of liver damage and levels of serum GOT and GPT tended to be lower in Group A than in Group B. In this clinical study the incidence of liver damage tended to be lowere in patients treated with Ge-132. The liver damage which often develops during intensificantion chemotherapy, not only limits the chemotherapy but also causes adverse effects on the quality of life of the patient. In part 1 of this series, Ge-132 was reported to activate the neutrophil chemiluminescence. Ge-132 seems to be useful in the management of ANLL patients not only by the enhancement of the host defense system but also by the prevenation of liver damage. en-copyright= kn-copyright= en-aut-name=FukumotoMitsuhiro en-aut-sei=Fukumoto en-aut-mei=Mitsuhiro kn-aut-name=福本光宏 kn-aut-sei=福本 kn-aut-mei=光宏 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=Ge-132 kn-keyword=Ge-132 en-keyword=Biological response modifier kn-keyword=Biological response modifier en-keyword=Acute nonlymphocytic leukemia kn-keyword=Acute nonlymphocytic leukemia en-keyword=Immunotherapy kn-keyword=Immunotherapy END start-ver=1.4 cd-journal=joma no-vol=104 cd-vols= no-issue=9-10 article-no= start-page=915 end-page=922 dt-received= dt-revised= dt-accepted= dt-pub-year=1992 dt-pub=199210 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Development of double cancer in small cell lung cancer patients treated with intensive chemotherapy kn-title=肺小細胞癌化学療法実施例における重複癌の発生に関する研究 en-subtitle= kn-subtitle= en-abstract= kn-abstract=Development of double cancer was evaluated in 337 small cell lung cancer patients who had received intensive chemotherapy with or without radiotherapy. Of them, 14 patients (4.2%) developed a second malignancy: non-small cell lung cancer in six, stomach cancer in four, acute myelogenous leukemia in two, liver cancer in one, and esophagus cancer in one. The relative risk for the development of double cancer calculated by person-year method utilizing age and sex adjusted cancer incidence in Japan was 2.75-fold (P<0.01). The risk of non-small cell lung cancer (8.75-fold) and acute myelogenous leukemia (37.82-fold) was particularly high. The cumulative risk for the development of double cancer was 2.0% at 1 year, 4.1% at 2 years, 14.3% at 3 years, and 100% at 8.1 years. Of 27 patients who survived disease-free for more than 2 years, 10 patients died; five patients (50%) died of double cancer, two died of infectious disease, and only three patients died from recurrent small cell lung cancer. These findings indicate that a cautious follow-up program for the detection of double cancer is indicated in patients with small cell lung cancer. en-copyright= kn-copyright= en-aut-name=MiyakeKenichi en-aut-sei=Miyake en-aut-mei=Kenichi kn-aut-name=三宅賢一 kn-aut-sei=三宅 kn-aut-mei=賢一 aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第二内科学教室 en-keyword=肺小細胞癌 kn-keyword=肺小細胞癌 en-keyword=化学療法 kn-keyword=化学療法 en-keyword=重複癌 kn-keyword=重複癌 END